Tenaya Therapeutics, Inc.

Tenaya Therapeutics (TNYA) has registered zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, the absence of recent adverse signals does not eliminate underlying risks—particularly dilution exposure and financing pressures common to clinical-stage biotech firms. The full $49 Report extends analysis to 12 months of SEC filings, quantifies dilution risk through our proprietary scoring model, maps the complete financing history, and flags AI-detected risk signals that may not yet surface in public events. The full $49 Report adds dilution risk score, 12-month 8-K context, financing trajectory analysis, and AI risk signal detection.